CAR T cells targeting Nectin-4 safely overcome resistance to anti-Nectin-4 antibody-drug conjugate in solid tumors

Abstract excerpt

<title>Abstract</title> <p>CAR-T cell therapy to solid tumors faces substantial challenges. Lack of tumor specific antigen (TSA) predicts toxicities in vital organs. Nectin-4 is a cell adhesion molecule expressed at different levels in many solid tumors, including breast and urothelial carcinoma (UC). Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) against Nectin-4, has significantly improved survival i...

Topics

Open a Topic to create a Post that cites this publication.

• Bladder and Urothelial Cancer Treatments
• CAR-T cell therapy research
• Immune Cell Function and Interaction
• Renal cell carcinoma treatment
• Respiratory viral infections research
• Urinary and Genital Oncology Studies
• Vector-Borne Animal Diseases
• Virology and Viral Diseases

Identifiers and source

Literature Corpus work

b4983d19-9bbf-5a34-b22c-1d014cc6a667

DOI

10.21203/rs.3.rs-8030850/v1